an alternative avenue to a takeover/cap raise is licensing
CSL dived into a RNA deal lately, with small US based minnow private biotech, who is set to receive a total of 4 potential income streams:
immediate:
1) $US 200m upfront, or $313m AUD
additional/potential future:
2) $US $4.3 B for achieving dev milestones
3) 40% profit share of future products
4) double digit royalties from future product sales
https://www.reuters.com/business/healthcare-pharmaceuticals/australias-csl-mrna-vaccine-licensing-deal-with-arcturus-2022-11-01/
not bad for such an early stage biotech, hopefully PYC’s more capable platform can achieve a superior deal if it ever comes to this
an alternative avenue to a takeover/cap raise is licensing CSL...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.005(0.44%) |
Mkt cap ! $662.0M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.14 | $13.69K | 12.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5941 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 13563 | 4 |
View Market Depth
| Last trade - 10.49am 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |